Investments (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017	Jul. 27, 2018
Schedule of Equity Method Investments [Line Items]
Equity Securities without Readily Determinable Fair Value, Amount	$ 314,000	$ 277,000
Proceeds from sale of available-for-sale securities	233,000	45,000	$ 29,000
Equity Securities with Readily Determinable Fair Value, Amount	14,000
Unrealized gain on equity investment	14,112	0	$ 0
Equity Method Investments	$ 9,000	$ 5,000
Related Party Transaction, Description of Transaction	Concurrently with the execution of the SPA, we announced a strategic operating relationship with Lumeris Healthcare Outcomes, LLC ("Lumeris"), a subsidiary of Essence Group, pursuant to which we will collaborate to bring to market an EHR-agnostic offering, Maestro AdvantageTM, designed to help providers who participate in value-based arrangements, including Medicare Advantage and provider-sponsored health plans, control costs and improve outcomes. Additionally, in July 2018, we sold certain solutions to Lumeris for an aggregate contract value of $28 million, of which we recognized $12 million and $5 million as revenues in 2019 and 2018, respectively
Essence Group Holdings Corporation [Member]
Schedule of Equity Method Investments [Line Items]
Equity Securities without Readily Determinable Fair Value, Amount				$ 266,000